Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

“The benefit-risk profile favored Pola-R-CHP vs R-CHOP in elderly patients with previously untreated DLBCL. Results were consistent with those of the overall POLARIX population and suggest that ...

Onward Therapeutics SA’s subsidiary Emercell SAS has received investigational medicinal product dossier (IMPD) approval from the EMA to initiate a phase I trial of OT-C001, an allogeneic natural ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

Roche RHHBY announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line ...

Patients aged 80+ with DLBCL show lower survival rates and higher treatment failure compared to younger groups. Older patients often have less education, live in more deprived areas, and ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

It is estimated that more than 80,500 DLBCL cases are reported worldwide each year. In May 2023, the US Food and Drug Administration (FDA) approved Imugene’s investigational new drug application ...

The European Commission has approved Roche's Columvi as the first bispecific antibody for the treatment of diffuse large ...